Multiple Beneficial Effects of Estrogen on Lipoprotein Metabolism
Robert H. Knopp and
Xiaodong Zhu
University of Washington
Northwest Lipid Research Clinic
Seattle, Washington 98104
Address correspondence and requests for reprints to: Robert H. Knopp, M.D., University of Washington, Northwest Lipid Research Clinic, 326 Ninth Avenue, #359720, Seattle, Washington 98104.
 |
Introduction
|
---|
The effects of estrogen on physiological systems
have fascinated endocrinologists for generations. Over the past
generation, it has become clear that estrogen affects lipoprotein
metabolism at many points and in many potentially beneficial ways, to
the point where estrogen as a prophylactic for cardiovascular disease
prevention has entered general medical practice, well out of the domain
of the specialist endocrinologist (1). The report of Campos et
al. (2) in this issue of JCEM (see page 3955) adds to
our understanding of why the effects of estrogen on lipoprotein
metabolism are beneficial and at what points they are beneficial.
The results of Campos et al. (2), show that the
hypertriglyceridemia associated with estrogen therapy, in this case 2
mg estradiol 17ß daily, given in the micronized form for 6 weeks is
associated with an increase in light, or buoyant, very low density
lipoprotein (VLDL). Smaller, more dense, and less buoyant forms of
lipoproteins, including dense VLDL and intermediate density
lipoproteins, did not increase in their concentrations. The reduction
in LDL was associated primarily with the reduction in light LDL with no
change in the smaller, more dense LDL.
As a generalization, the rates of formation of all lipoprotein
fractions are increased under the influence of estrogen (Fig. 1
), but their removal rates are variably
increased, so that most of the fractions except the light VLDL fraction
do not increase, or as in the case of light LDL, actually decrease.
Particularly notable is the fact that the intermediate density
lipoprotein, a very atherogenic species in its own right, does not
increase with estrogen therapy, again because the rate of removal keeps
pace with the rate of production.

View larger version (19K):
[in this window]
[in a new window]
|
Figure 1. Effects of sex steroids on lipid metabolism.
Width of lines indicate the rate of cholesterol traffic under influence
of estrogen (L) or progestin/androgen (R). Question marks indicate
effects for which documentation is uncertain or unclear. Modified from
Reference 26 with permission.
|
|
What are the implications of these changes in both concentration and
rate of lipoprotein transport in the bloodstream for arteriosclerotic
vascular disease? Regarding the increase in light VLDL concentration
and rate of transport, the authors suggest that the rapid rate of
transfer through the blood stream reduces the amount of time for
oxidation and for the remodeling of the lipoprotein by acquisition of
cholesterol from other lipoproteins, such as HDL. The lack of a
cholesterol rise in the light VLDL fraction, despite the increase in
the triglyceride concentration, is consistent with this effect and has
been observed previously (3). Additional reasons for the lack of
atherogenicity of light VLDL may be offered. One is that families of
hypertriglyceridemic individuals have been observed without heart
disease and with this particular kind of buoyant noncholesterol
enriched VLDL (4, 5). Another reason is that the larger size of
buoyant, light VLDL limits infiltration into the arterial intima and
the amount of cholesterol likely to be trapped (6). Thus, there are
several metabolic and physical reasons to believe that the
hypertriglyceridemia of estrogen therapy is nonatherogenic.
Much more likely to be atherogenic are those conditions associated with
increases in the less buoyant or dense VLDL, typically in individuals
who have familial combined hyperlipidemia (5). Dense VLDL is more
likely to be retained in the arterial wall, causing atherogenesis
(6). According to Campos et al. (2), concentrations of this
subfraction are not increased at all with estrogen therapy, neither in
cholesterol, triglyceride, or apo B moieties. In addition, the more
rapid rate of transport in the bloodstream or flux of dense VLDL might
render it less atherogenic than would be expected, as discussed
above.
The intermediate density lipoprotein (IDL), which approximates the
remnant lipoprotein (Fig. 1
), deserves special mention in the
consideration of the effects of estrogen on lipoprotein metabolism. In
these normal subjects studied by Campos et al. (2), there
was no change in pool size and no change in production or removal
rates, but estrogen nonetheless had an effect on the origin and fate of
IDL, a lesser proportion formed directly, a greater portion formed from
dense VLDL, a lesser amount directly removed and a greater amount
converted to light and dense LDL. These alterations may have no
significance for atherogenesis. Nonetheless, one of the earliest
described beneficial effects of estrogen was to lower plasma
triglyceride levels and to lower the IDL fraction in individuals with
Type III hyperlipidemia, or remnant removal disease (7, 8). Presumably
the reason for the decrease in IDL, or remnant levels in Type III with
estrogen therapy is the upregulation of the LDL receptor, rather than
any direct effect on hepatic lipase, which is reduced by estrogen (3)
and would be expected to impede remnant clearance. The lack of change
in IDL concentrations in the normal subjects of Campos et
al. (2) may be a consequence of the interplay between an increase
in LDL receptor activity and a decrease in hepatic lipase activity.
From the standpoint of atherogenesis, it is very important to keep in
mind that the intermediate density particle is highly atherogenic, as
shown by Tatami et al. as early as 1981 (9) and others since
(see reference 10 for review). It would be interesting to know the
effect of estrogen on IDL and dense VLDL in the hyperlipidemic
populations of women at higher risk for cardiovascular disease.
Regarding low density lipoprotein (LDL), the study of Campos et
al. (2) resolves what has until now been a perplexing
questionhow can a beneficial effect of estrogen be derived from a
change in LDL composition toward a smaller, more dense particle, which
is associated with greater atherogenicity (11)? Campos et
al. conclusively show that the estrogen-induced reduction in LDL
is in the light form, while the level of the dense form remains
unchanged. Such a reduction is associated with diminished coronary
artery disease. For instance, in the original Coronary Primary
Prevention Trial of 1984 (12) the bile-acid binding drug
cholestyramine attained a reduction in LDL and coronary artery
disease. The LDL reduction associated with this treatment occurs in the
more buoyant LDL form (13). Similarly, reductase inhibitor therapy
lowers cholesterol without actually changing the LDL subclass pattern
from buoyant (pattern A) to more dense (pattern B) (14), yet is highly
successful in preventing coronary disease (14). Estrogen therapy
appears to be not unlike these more classical treatments, where the
reduction in the more buoyant LDL form allows the more dense LDL to
remain, but a reduction in coronary disease risk still results. Again,
as in the other lipoprotein fractions, the more rapid rate of turnover
of LDL remaining in the circulation should allow for less lipoprotein
remodeling, less acquisition of cholesterol from HDL, and less exposure
to oxidative stress.
What are some of the practical implications of these observations
for general health? First of all, an estrogen-induced triglyceride rise
is not without clinical importance when the patient has an elevated
triglyceride level before treatment or develops very elevated
triglyceride levels with treatment. Thus, in individuals with elevated
triglyceride levels at baseline of 300 mg/dL (
3.4 mmol/L), estrogen
administration in the form of oral contraceptives or postmenopausal
oral replacement therapy can raise the plasma triglyceride to the
danger level for pancreatitis, which is above 1,000 mg/dL (8.86
mmol/L). In this instance we routinely suggest that women taking oral
postmenopausal hormone replacement switch to patch estrogen, which
avoids the plasma triglyceride increase by circumventing the hepatic
first pass effect and avoids stopping the estrogen. Unfortunately, most
of the lipoprotein effects of oral estrogen therapy are also lost, but
it should be kept in mind that the systemic circulation is the
physiological route of entry of estrogen into the body.
Recently, the focus on mechanisms of the vascular benefit of estrogen
has expanded to direct arterial wall effects, which include diminished
penetration of LDL into the arterial wall (15), diminished retention of
LDL in the arterial wall (16), diminished susceptibility of LDL to
oxidation (17), improved arterial vasomotion (18), and diminished
arterial susceptibility to injury (19) (Table 1
). Indeed, women with Prinzmetal or
vasospastic angina may improve with estrogen replacement therapy (20),
further justifying the interest of our cardiologist colleagues in the
hormonal management of coronary artery disease.
Finally, it cannot be assumed that beneficial effects of estrogen on
lipoprotein metabolism and arterial wall biology will be preserved or
will be equivalent in degree in the presence of concomitant progestin
therapy. While the metabolism of lipoproteins is generally enhanced
under the influence of estrogen, as elegantly documented by Campos
et al. (2), progestins tend to inhibit this rate of
metabolism by acting as an antiestrogen (Fig. 1
) (1). In this respect
it is important to note that certain progestins cannot only have
antiestrogenic effects based on receptor-mediated mechanisms but can
also potentiate oxidative damage to LDL, as recently shown by Zhu
et al. (17). Indeed, one progestin, medroxyprogesterone
acetate, cancels the antiatherosclerotic and vasodilator effects of
estrogen in a subhuman primate model of atherosclerosis (21, 22). Thus,
the opposition of estrogen effects by progestins, which every
endocrinologist recognizes, needs to be kept in mind by practitioners
in general, to the extent that risk from coronary artery disease cannot
automatically be expected to be reduced to the same degree in combined
therapy as with estrogen therapy alone. Progestin type is also likely
to be important, as shown by the PEPI study (23), where natural
progesterone was less adverse in effects on lipoproteins, clotting, and
carbohydrate metabolism than two doses of medroxyprogesterone acetate
2.5 mg daily, continuously or 10 mg daily, cyclically.
In conclusion, estrogen has multiple effects on lipoprotein metabolism,
largely to enhance the rate of transport in the blood stream. This
adaptation probably serves a reproductive need by enhancing the
availability of lipoprotein-born cholesterol and fatty acids to the
ovary and placenta for endocrine steroidogenesis and for the growth and
development of the fetus. Perhaps not surprisingly, nature has provided
an apparent survival benefit with estrogen in respect to cardiovascular
disease susceptibility and many other body systems such as
osteoporosis, skin, and higher integrative functions. Future research
should be directed toward refining our understanding of the
interactions between estrogens and antiestrogens on these systems of
the body, as well as the effects of selective-estrogen response
modulators (SERMs), which may embody estrogen and progestin effects in
the same molecule (24) or only selectively affect estrogen receptors in
certain systems (25). In the meantime, the elegant study of Campos and
associates (2) reminds us that estrogen must be one of natures most
favored hormones!
Received October 1, 1997.
Accepted October 1, 1997.
 |
References
|
---|
-
Knopp RH, Zhu X-D, Lau J, Walden C. 1994 Sex
hormones and lipid interactions: implications for cardiovascular
disease in women. The Endocrinologist. 4:286301.
-
Campos H, Walsh BW, Judge H, Sacks FM. 1997 Effect
of estrogen on VLDL and LDL metabolism in postmenopausal women. J
Clin Endocrinol Metab. 82:39553963.[Abstract/Free Full Text]
-
Applebaum-Bowden D, McLean P, Steinmetz, et al. 1989 Lipoprotein, apolipoprotein an lypolytic enzyme changes following
estrogen administration in postmenopausal women. J Lipid Res. 30:18951906.[Abstract]
-
Brunzell JD, Schrott HG, Motulsky AG, Bierman EL. 1976 Myocardial infarction in the familial forms of
hypertriglyceridemia. Metabolism. 25:313320.[Medline]
-
Brunzell JD, Albers JJ, Chait A, Grundy SM, Groszek E,
McDonald GB. 1983 Plasma lipoproteins in familial combined
hyperlipidemia and monogenic familial hypertriglyceridemia. J Lipid
Res. 24:147155.[Abstract/Free Full Text]
-
Rapp JH, Lespine A, Hamilton RL, et al. 1994 Triglyceride-rich lipoproteins isolated by selected-affinity
anti-apolipoprotein B immunosorption from human atherosclerotic plaque. Arterioscler Thromb. 14:17671774.[Abstract]
-
Feldman EB, Wang CI, Adelsberg D. 1959 Effect of
prolonged use of estrogen on circulating lipids in patients with
idiopathic hyperlipidemia. Circulation. 20:234242.[Medline]
-
Chait A, Brunzell JD, Albers JJ, et al. 1977 Type
III hyperlipoproteinemia ("remnant removal disease"): insight into
the pathogenic metabolism. Lancet. 1:11761178.[Medline]
-
Tatami R, Mabuchi H, Ueda K, et al. 1981 Intermediate-density lipoprotein and cholesterol-rich VLDL in
angiographically determined coronary artery disease. Circulation. 64:11741183.[Abstract]
-
Broyles FE, Walden CE, Hunninghake DB, Hill-Williams D,
Knopp RH. 1995 Effect of fluvastatin on intermediate density
lipoprotein (remnants) and other lipoprotein levels in
hypercholesterolemia. Am J Cardiol. 72(2):A12935.
-
Campos H, Sacks FM, Walsh BW, Schiff I, OHanesian MA,
Krauss RM. 1993 Differential effects of estrogen on low-density
lipoprotein subclasses in healthy postmenopausal women. Metabolism. 42:11531158.[Medline]
-
Lipid Research Clinics Program. 1984 The Lipid
Research Clinics Coronary Primary Prevention Trial Results. I.
Reduction in incidence of coronary heart disease. JAMA.
251(3):351364.
-
Witztum JL, Schonfeld G, Weidman SW, Giese WE,
Dillingham MA. 1979 Bile sequestrant therapy alters the
composition of low-density and high-density lipoproteins. Metabolism. 28:221229.[Medline]
-
Cheung MC, Austin MA, Moulin P, Wolf AC, Cryer D, Knopp
RH. 1993 Effects of pravastatin on apoprotein-specific high
density lipoprotein subpopulations and low density lipoprotein subclass
phenotypes in patients with primary hypercholesterolemia. Atherosclerosis. 102:107119.[Medline]
-
Wagner JD, Clarkson TB, St. Clair RW, Schwenke DC,
Shively CA, Adams MR. 1991 Estrogen and progesterone therapy
reduces low density lipoprotein accumulation in the coronary arteries
of surgically postmenopausal monkeys. J Clin Invest. 88:19952002.[Medline]
-
Haarbo J, Nielson LB, Stander S, Christiansen C. 1994 Aortic permeability to LDL during estrogen therapy: a study in
normocholesterolemic subjects. Arterioscler Thromb. 14:243247.[Abstract]
-
Zhu X-D, Bonet B, Knopp RH. 1997 17ß-estradiol,
progesterone and testosterone inversely modulate low-density
lipoprotein oxidation and cytotoxicity in cultured placental
trophoblast and macrophages Am J Obstet Gynecol. 177:196209.[Medline]
-
Herrington DM, Braden GA, Williams JK, Morgan TM. 1994 Endothelial-dependent coronary vasomotor responsiveness in
postmenopasualk women with and without estrogen replacement therapy. Am J Cardiol. 73:951952.[Medline]
-
Sullivan TR Jr, Karas RH, Aronovitz M, et al. 1995 Estrogen inhibits a response-to-injury in a mouse carotid artery model. J Clin Invest. 96:24822488.[Medline]
-
Guetta V, Cannon III RO. 1996 Cardiovascular
effects of estrogen and lipid-lowering therapies in postmenopausal
women. 93:19281937.
-
Adams MR, Register TC, Golden DL, Wagner JD,
Williams JK. 1997 Medroxyprogesterone acetate antagonizes
inhibitory effects of conjugated equine estrogens on coronary artery
atherosclerosis. Artereioscler Thromb. 17:217221.[Abstract/Free Full Text]
-
Miyagawa K, Rosch J, Stanczyk F, Hermsmeyer K. 1997 Medroxyprogesterone interferes with ovarian steroid protection against
coronary vasospasm. Nature Med. 3:324327.[Medline]
-
The Writing Group for the PEPI Trial. 1995 Effects
of estrogen or estrogen/progestin regimens on heart disease risk
factors in postmenopausal women: the postmenopausal estrogen/progestin
intervention trial. JAMA. 273:199208.[Abstract]
-
Davies TF. 1996 Editorial: Tibilone as an
alternative to estrogen for the prevention of postmenopausal
osteoporosis in selected postmenopausal women. J Clin Endocrinol
Metab. 81:24172418.[Medline]
-
Paech K, Webb P, Kuiper GGJM, et al. 1997 Differential ligand activation of estrogen receptors ER
and ERß at
AP1 sites. Science. 277:15081510.[Abstract/Free Full Text]
-
Knopp RH. 1989 The effects of oral contraceptives
and postmenopausal estrogens on lipoprotein physiology and
atherosclerosis. In: Halbe HW, Rekers H, eds. Oral contraception into
the 1990s. Carnforth, UK: Parthenon Publishing: 3145.